MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover Trial
| العنوان: | MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover Trial |
|---|---|
| المؤلفون: | Eran Atlas, Shahar Miller, Aviel Fogel, Tadej Battelino, Natasa Bratina, Ido Muller, Revital Nimri, Olga Kordonouri, Moshe Phillip, Thomas Danne |
| المصدر: | Diabetes Care. 37:3025-3032 |
| بيانات النشر: | American Diabetes Association, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Hypoglycemia, law.invention, Young Adult, Insulin Infusion Systems, Randomized controlled trial, law, Interquartile range, Diabetes mellitus, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Insulin, Child, Glycemic, Advanced and Specialized Nursing, Type 1 diabetes, Cross-Over Studies, business.industry, medicine.disease, Crossover study, Surgery, Diabetes Mellitus, Type 1, Hyperglycemia, Anesthesia, Female, business |
| الوصف: | OBJECTIVE We evaluated the effect of the MD-Logic system on overnight glycemic control at patients' homes. RESEARCH DESIGN AND METHODS Twenty-four patients (aged 12–43 years; average A1c 7.5 ± 0.8%, 58.1 ± 8.4 mmol/mol) were randomly assigned to participate in two overnight crossover periods, each including 6 weeks of consecutive nights: one under closed loop and the second under sensor-augmented pump (SAP) therapy at patients' homes in real-life conditions. The primary end point was time spent with sensor glucose levels below 70 mg/dL (3.9 mmol/L) overnight. RESULTS Closed-loop nights significantly reduced time spent in hypoglycemia (P = 0.02) and increased the percentage of time spent in the target range of 70–140 mg/dL (P = 0.003) compared with nights when the SAP therapy was used. The time spent in substantial hyperglycemia above 240 mg/dL was reduced by a median of 52.2% (interquartile range [IQR] 4.8, 72.9%; P = 0.001) under closed-loop control compared with SAP therapy. Overnight total insulin doses were lower in the closed-loop nights compared with the SAP nights (P = 0.04). The average daytime glucose levels after closed-loop operation were reduced by a median of 10.0 mg/dL (IQR −2.7, 19.2; P = 0.017) while lower total insulin doses were used (P = 0.038). No severe adverse events occurred during closed-loop control; there was a single event of severe hypoglycemia during a control night. CONCLUSIONS The long-term home use of automated overnight insulin delivery by the MD-Logic system was found to be a feasible, safe, and an effective tool to reduce nocturnal hypoglycemia and improve overnight glycemic control in subjects with type 1 diabetes. |
| تدمد: | 1935-5548 0149-5992 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f277a7aa863b4e30e8885d9ea2c1296Test https://doi.org/10.2337/dc14-0835Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....0f277a7aa863b4e30e8885d9ea2c1296 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19355548 01495992 |
|---|